Keith Gottesdiener, Prime Medicine CEO
September 30, 2024 07:35 AM EDTUpdated 11:31 AM
Deals
R&D

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

Lei Lei Wu

News Reporter

Prime Med­i­cine is cut­ting its pipeline, but gain­ing a part­ner.

The gene edit­ing com­pa­ny, which once boast­ed a pipeline of 18 pro­grams, is now fo­cus­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines

Po­sei­da shares in­cre­men­tal Phase 1 up­date for Roche-part­nered off-the-shelf CAR-T

Lil­ly-part­nered ra­dio­phar­ma start­up Ak­tis On­col­o­gy rais­es $175M

For some mul­ti­ple myelo­ma pa­tients, Carvyk­ti cut risk of death by 45%

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times